<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266042</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-M-REG01</org_study_id>
    <nct_id>NCT03266042</nct_id>
  </id_info>
  <brief_title>Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy</brief_title>
  <official_title>Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delcath Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delcath Systems Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have
      Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of
      Unresectable Hepatic Malignancy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post Marketing study:

      The CHEMOSAT kit containing Gen 2 filters has been used to treat patients since April 2011.
      This registry study is designed to collect the treatment outcome in patients who receive this
      treatment and use experience of the CHEMOSAT Kits by healthcare professionals. The safety and
      efficacy data from patients treated in the commercial setting is important in updating the
      safety profile as well as the risk/benefit of the treatment. The resource utilization
      information is essential in planning treatment strategy for patients.

      This registry does not follow any pre-determined protocol with respect to diagnosis,
      treatment or follow-up of the patient. The data collected will be gathered exclusively from
      current medical practice at participating institutions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter).</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Data to be collected at: Baseline, treatment and post treatment laboratory values and clinical measurements until time of discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect Safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Length of post-op hospital stay: ICU, step-down unit or general ward</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Blood product use: RBC, platelets, plasma and plasma fractions with prophylactic or therapeutic intention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Hospital admission within 30 days following treatment and reasons for hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Disease and treatment related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Device malfunction requiring remediation and/or changes to the treatment or procedure-related complication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>• Supportive care:
Growth factors, prophylactic or therapeutic
Antibiotics, prophylactic or therapeutic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To gather key safety data on the use of CHEMOSAT Kit (Gen 2 filter). Data to</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>Performance Status and tumor related symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain essential efficacy information in these patients using RECIST 1.1:</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>• Hepatic response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect essential efficacy information in these patients using RECIST 1.1:</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>• Time to partial response or complete response, when applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtain essential efficacy information in these patients using RECIST 1.1:</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>• Time to liver metastasis progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtain essential efficacy information in these patients using RECIST 1.1:</measure>
    <time_frame>Post-procedure (up to 30 days after CS-PHP)</time_frame>
    <description>• Time to extra-hepatic disease progression</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatic Malignant Neoplasm Primary Non-Resectable</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have
        Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of
        Unresectable Hepatic Malignancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has received Melphalan-PHP treatment.

          2. Has provided written informed consent according to institutional and regulatory
             guidelines

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leslie Callahan, BSN, MS</last_name>
    <phone>212-489-2100</phone>
    <phone_ext>247</phone_ext>
    <email>lcallahan@delcath.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Riebel, MBA</last_name>
    <phone>212-489-2100</phone>
    <phone_ext>238</phone_ext>
    <email>nriebel@delcath.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt - Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Vogl, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pradesh Kumar, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals and University of Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Karydis, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spire Southampton Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Gupta, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

